Trial Profile

Phase II multi-centre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary)
Indications Type 1 diabetes mellitus
Focus Pharmacokinetics
Acronyms USTEK1D; USTEKID

Most Recent Events

01 Sep 2024 Results assessing the effect of Ustekinumab for type 1 diabetes in adolescents published in the Nature Medicine
06 Oct 2023 Results assessing beta cell (pancreatic islets) function and to find a marker/ a composite of markers that reflect the function/ health of the pancreas in people with T1D presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
17 Jun 2021 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com